The second-generation DLL3-targeted CAR T-cell therapy AMG119, incorporating a 4-1BB (CD137) costimulatory domain, demonstrated durable tumor-killing effects in preclinical SCLC xenograft models (97, 98). The gene discussed is TNFRSF9; the disease is neoplasm.